339 related articles for article (PubMed ID: 27759713)
1. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
Raj N; Valentino E; Capanu M; Tang LH; Basturk O; Untch BR; Allen PJ; Klimstra DS; Reidy-Lagunes D
Pancreas; 2017 Mar; 46(3):296-301. PubMed ID: 27759713
[TBL] [Abstract][Full Text] [Related]
2. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
3. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
4. Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.
Pulvirenti A; Raj N; Cingarlini S; Pea A; Tang LH; Luchini C; Chou JF; Grego E; Marinova I; Capanu M; Landoni L; Scarpa A; Allen PJ; Klimstra DS; Reidy-Lagunes DL
Pancreas; 2021 Feb; 50(2):138-146. PubMed ID: 33565789
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
[TBL] [Abstract][Full Text] [Related]
6. High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification: A Validation Study From a Single-Institution Retrospective Analysis.
Hayes AR; Furnace M; Shah R; Rundell C; Muller G; Dehbi HM; Luong TV; Toumpanakis C; Caplin ME; Krell D; Thirlwell C; Mandair D
Pancreas; 2021 Apr; 50(4):516-523. PubMed ID: 33939663
[TBL] [Abstract][Full Text] [Related]
7. Rb Loss and
Hijioka S; Hosoda W; Matsuo K; Ueno M; Furukawa M; Yoshitomi H; Kobayashi N; Ikeda M; Ito T; Nakamori S; Ishii H; Kodama Y; Morizane C; Okusaka T; Yanagimoto H; Notohara K; Taguchi H; Kitano M; Yane K; Maguchi H; Tsuchiya Y; Komoto I; Tanaka H; Tsuji A; Hashigo S; Kawaguchi Y; Mine T; Kanno A; Murohisa G; Miyabe K; Takagi T; Matayoshi N; Yoshida T; Hara K; Imamura M; Furuse J; Yatabe Y; Mizuno N
Clin Cancer Res; 2017 Aug; 23(16):4625-4632. PubMed ID: 28455360
[No Abstract] [Full Text] [Related]
8. Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms.
Shi H; Chen L; Zhang Q; Lin Y; Jiang C; Yao H; Hou X; Chen M; Lin R; Chen J
Pancreas; 2020; 49(10):1378-1382. PubMed ID: 33122528
[TBL] [Abstract][Full Text] [Related]
9. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.
Singhi AD; Klimstra DS
Histopathology; 2018 Jan; 72(1):168-177. PubMed ID: 29239037
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
11. Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
Panzuto F; Rinzivillo M; Spada F; Antonuzzo L; Ibrahim T; Campana D; Fazio N; Delle Fave G
Pancreas; 2017 Mar; 46(3):302-305. PubMed ID: 28099254
[TBL] [Abstract][Full Text] [Related]
12. Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.
Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
Cancer Cytopathol; 2018 Jan; 126(1):44-53. PubMed ID: 29044913
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
[TBL] [Abstract][Full Text] [Related]
14. Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma.
Bajetta E; Catena L; Biondani P; Pusceddu S; Valente M; Bianco N; Novelli E
Anticancer Res; 2014 Oct; 34(10):5657-60. PubMed ID: 25275070
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
16. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups.
Tanaka H; Hijioka S; Hosoda W; Ueno M; Kobayashi N; Ikeda M; Ito T; Kodama Y; Morizane C; Notohara K; Taguchi H; Kitano M; Komoto I; Tsuji A; Hashigo S; Kanno A; Miyabe K; Takagi T; Ishii H; Kojima Y; Yoshitomi H; Yanagimoto H; Furuse J; Mizuno N
Pancreatology; 2020 Oct; 20(7):1421-1427. PubMed ID: 32891532
[TBL] [Abstract][Full Text] [Related]
18. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors.
Simon T; Riemer P; Jarosch A; Detjen K; Di Domenico A; Bormann F; Menne A; Khouja S; Monjé N; Childs LH; Lenze D; Leser U; Rossner F; Morkel M; Blüthgen N; Pavel M; Horst D; Capper D; Marinoni I; Perren A; Mamlouk S; Sers C
Genome Med; 2022 Mar; 14(1):24. PubMed ID: 35227293
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication.
Taskin OC; Clarke CN; Erkan M; Tsai S; Evans DB; Adsay V
J Gastrointest Oncol; 2020 Jun; 11(3):548-558. PubMed ID: 32655934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]